GTx, Inc.
(NASDAQ : GTXI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.38%183.681.1%$863.43m
GILDGilead Sciences, Inc.
-0.27%80.720.9%$828.00m
CELGCelgene Corporation
1.04%94.831.2%$768.83m
JUNOJuno Therapeutics, Inc.
1.96%86.6513.5%$580.24m
BIIBBiogen Inc.
0.48%288.831.2%$512.39m
REGNRegeneron Pharmaceuticals, Inc.
-1.09%319.522.7%$396.38m
VRTXVertex Pharmaceuticals Incorporated
-1.56%158.471.9%$353.75m
ALXNAlexion Pharmaceuticals, Inc.
-0.44%118.332.0%$255.49m
NKTRNektar Therapeutics
1.49%84.696.0%$250.72m
ILMNIllumina, Inc.
0.01%226.583.5%$230.72m
BLUEBluebird Bio, Inc.
2.04%209.6516.1%$195.88m
AAgilent Technologies, Inc.
1.44%72.101.5%$178.13m
INCYIncyte Corporation
0.52%85.952.5%$154.91m
BMRNBioMarin Pharmaceutical Inc.
1.06%84.734.4%$122.45m
EXASExact Sciences Corporation
-0.23%47.9026.0%$117.89m

Company Profile

GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.